Targeting the Glycoprotein 130 Receptor Subunit to Control Pain and Inflammation
Publication: Journal of Interferon & Cytokine Research
Volume 30, Issue Number 12
Abstract
The glycoprotein 130 (gp130) is a shared signal-transducing-membrane-associated receptor for several hematopoietic cytokines. Its activation is implicated in pain and in a variety of diseases via signaling of proinflammatory cytokines. These include interleukin-6 (IL-6) subfamily cytokines, many of which play important roles in the pathogenesis of diseases such as rheumatoid arthritis, Castleman's disease, and Kaposi's sarcoma. Several strategies have been developed to block gp130-receptor-mediated signaling. These include the application of monoclonal antibodies, the creation of mutant form(s) of the gp130 with increased binding affinity for such ligands as IL-6/sIL-6R complex, and the generation of antagonists by selective mutagenesis of the specific cytokine/gp130 receptor binding site(s). Other strategies include targeting gp130-mediated signaling pathways such as that involving signal transducer and activator of transcription-3. This review provides a summary of the latest research pertaining to the role of gp130 in the pathogenesis of inflammatory and other diseases in which the gp130 receptor is implicated. An overview of antagonists targeting the gp130 receptor is included with particular emphasis on their mechanism of action and their limitations and potential for therapeutic application.
Get full access to this article
View all available purchase options and get full access to this article.
References
Ancey CKuster AHaan SHerrmann AHeinrich PCMuller-Newen G2003. A fusion protein of the gp130 and IL-6Ralpha ligand-binding domains acts as a potent IL-6 inhibitorJ Biol Chem2781916968-16972. Ancey C, Kuster A, Haan S, Herrmann A, Heinrich PC, Muller-Newen G. 2003. A fusion protein of the gp130 and IL-6Ralpha ligand-binding domains acts as a potent IL-6 inhibitor. J Biol Chem 278(19):16968–16972.
Andratsch MMair NConstantin CEScherbakov NBenetti CQuarta SVogl CSailer CAUceyler NBrockhaus JMartini RSommer CZeilhofer HUMuller WKuner RDavis JBRose-John SKress M2009. A key role for gp130 expressed on peripheral sensory nerves in pathological painJ Neurosci294313473-13483. Andratsch M, Mair N, Constantin CE, Scherbakov N, Benetti C, Quarta S, Vogl C, Sailer CA, Uceyler N, Brockhaus J, Martini R, Sommer C, Zeilhofer HU, Muller W, Kuner R, Davis JB, Rose-John S, Kress M. 2009. A key role for gp130 expressed on peripheral sensory nerves in pathological pain. J Neurosci 29(43):13473–13483.
Auernhammer CJZitzmann KSchnitzler FSeiderer JLohse PVlotides GEngelhardt DSackmann MGoke BOchsenkuhn T2005. Role of the intracellular receptor domain of gp130 (exon 17) in human inflammatory bowel diseaseWorld J Gastroenterol1181196-1199. Auernhammer CJ, Zitzmann K, Schnitzler F, Seiderer J, Lohse P, Vlotides G, Engelhardt D, Sackmann M, Goke B, Ochsenkuhn T. 2005. Role of the intracellular receptor domain of gp130 (exon 17) in human inflammatory bowel disease. World J Gastroenterol 11(8):1196–1199.
Borsellino NBonavida BCiliberto GToniatti CTravali SD'Alessandro N1999. Blocking signaling through the gp130 receptor chain by interleukin-6 and oncostatin M inhibits PC-3 cell growth and sensitizes the tumor cells to etoposide and cisplatin-mediated cytotoxicityCancer851134-144. Borsellino N, Bonavida B, Ciliberto G, Toniatti C, Travali S, D'Alessandro N. 1999. Blocking signaling through the gp130 receptor chain by interleukin-6 and oncostatin M inhibits PC-3 cell growth and sensitizes the tumor cells to etoposide and cisplatin-mediated cytotoxicity. Cancer 85(1):134–144.
Clarke SJSmith JTGebbie CSweeney COlszewski N2009. A phase I, pharmacokinetic (PK), and preliminary efficacy assessment of ALD518, a humanized anti-IL-6 antibody, in patients with advanced cancerJ Clin Oncol (Meeting Abstracts)2715S3025. Clarke SJ, Smith JT, Gebbie C, Sweeney C, Olszewski N. 2009. A phase I, pharmacokinetic (PK), and preliminary efficacy assessment of ALD518, a humanized anti-IL-6 antibody, in patients with advanced cancer. J Clin Oncol (Meeting Abstracts) 27(15S):3025.
Doganci ASauer KKarwot RFinotto S2005. Pathological role of IL-6 in the experimental allergic bronchial asthma in miceClin Rev Allergy Immunol283257-270. Doganci A, Sauer K, Karwot R, Finotto S. 2005. Pathological role of IL-6 in the experimental allergic bronchial asthma in mice. Clin Rev Allergy Immunol 28(3):257–270.
Dubinski AZdrojewicz Z2007. [The role of interleukin-6 in development and progression of atherosclerosis]Pol Merkur Lekarski22130291-294. Dubinski A, Zdrojewicz Z. 2007. [The role of interleukin-6 in development and progression of atherosclerosis]. Pol Merkur Lekarski 22(130):291–294.
Emery PKeystone ETony HPCantagrel Avan Vollenhoven RSanchez AAlecock ELee JKremer J2008. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-TNF biologics: results from a 24-week multicentre randomised placebo controlled trialAnn Rheum Dis67111516-1523. Emery P, Keystone E, Tony HP, Cantagrel A, van Vollenhoven R, Sanchez A, Alecock E, Lee J, Kremer J. 2008. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-TNF biologics: results from a 24-week multicentre randomised placebo controlled trial. Ann Rheum Dis 67(11):1516–1523.
Ernst MInglese MWaring PCampbell IBao SClay FAlexander WWicks ITarlinton DNovak UHeath JDunn A2001. Defective gp130-mediated signal transducer and activator of transcription (STAT) signaling results in degenerative joint disease, gastrointestinal ulceration, and failure of uterine implantationJ Exp Med1942189-203. Ernst M, Inglese M, Waring P, Campbell I, Bao S, Clay F, Alexander W, Wicks I, Tarlinton D, Novak U, Heath J, Dunn A. 2001. Defective gp130-mediated signal transducer and activator of transcription (STAT) signaling results in degenerative joint disease, gastrointestinal ulceration, and failure of uterine implantation. J Exp Med 194(2):189–203.
Febbraio MA2007. gp130 receptor ligands as potential therapeutic targets for obesityJ Clin Invest1174841-849. Febbraio MA. 2007. gp130 receptor ligands as potential therapeutic targets for obesity. J Clin Invest 117(4):841–849.
Fischer MGoldschmitt JPeschel CBrakenhoff JPKallen KJWollmer AGrotzinger JRose-John S1997. I. A bioactive designer cytokine for human hematopoietic progenitor cell expansionNat Biotechnol152142-145. Fischer M, Goldschmitt J, Peschel C, Brakenhoff JP, Kallen KJ, Wollmer A, Grotzinger J, Rose-John S. 1997. I. A bioactive designer cytokine for human hematopoietic progenitor cell expansion. Nat Biotechnol 15(2):142–145.
Goodman WALevine ADMassari JVSugiyama HMcCormick TSCooper KD2009. IL-6 signaling in psoriasis prevents immune suppression by regulatory T cellsJ Immunol18353170-3176. Goodman WA, Levine AD, Massari JV, Sugiyama H, McCormick TS, Cooper KD. 2009. IL-6 signaling in psoriasis prevents immune suppression by regulatory T cells. J Immunol 183(5):3170–3176.
Grotzinger JKernebeck TKallen KJRose-John S1999. IL-6 type cytokine receptor complexes: hexamer, tetramer or both?Biol Chem3807–8803-813. Grotzinger J, Kernebeck T, Kallen KJ, Rose-John S. 1999. IL-6 type cytokine receptor complexes: hexamer, tetramer or both? Biol Chem 380(7–8):803–813.
Gu ZJWijdenes JZhang XGHallet MMClement CKlein B1996. Anti-gp130 transducer monoclonal antibodies specifically inhibiting ciliary neurotrophic factor, interleukin-6, interleukin-11, leukemia inhibitory factor or oncostatin MJ Immunol Methods190121-27. Gu ZJ, Wijdenes J, Zhang XG, Hallet MM, Clement C, Klein B. 1996. Anti-gp130 transducer monoclonal antibodies specifically inhibiting ciliary neurotrophic factor, interleukin-6, interleukin-11, leukemia inhibitory factor or oncostatin M. J Immunol Methods 190(1):21–27.
Heinrich PCBehrmann IMuller-Newen GSchaper FGraeve L1998. Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathwayBiochem J334Pt 2297-314. Heinrich PC, Behrmann I, Muller-Newen G, Schaper F, Graeve L. 1998. Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochem J 334 (Pt 2):297–314.
Hibi MMurakami MSaito MHirano TTaga TKishimoto T1990. Molecular cloning and expression of an IL-6 signal transducer, gp130Cell6361149-1157. Hibi M, Murakami M, Saito M, Hirano T, Taga T, Kishimoto T. 1990. Molecular cloning and expression of an IL-6 signal transducer, gp130. Cell 63(6):1149–1157.
Hudson KRVernallis ABHeath JK1996. Characterization of the receptor binding sites of human leukemia inhibitory factor and creation of antagonistsJ Biol Chem2712011971-11978. Hudson KR, Vernallis AB, Heath JK. 1996. Characterization of the receptor binding sites of human leukemia inhibitory factor and creation of antagonists. J Biol Chem 271(20):11971–11978.
Inta IWeber DGrundt CVeltkamp RWinteroll SAuffarth GUBettendorf MLemmer BrSchwaninger M2009. Correlation of soluble gp130 serum concentrations with arterial blood pressureJ Hypertens273527-534. Inta I, Weber D, Grundt C, Veltkamp R, Winteroll S, Auffarth GU, Bettendorf M, Lemmer Br, Schwaninger M. 2009. Correlation of soluble gp130 serum concentrations with arterial blood pressure. J Hypertens 27(3):527–534.
Jazayeri JACarroll GJ2008. Fc-based cytokines: prospects for engineering superior therapeuticsBioDrugs22111-26. Jazayeri JA, Carroll GJ. 2008. Fc-based cytokines: prospects for engineering superior therapeutics. BioDrugs 22(1):11–26.
Jostock TBlinn GRenne CKallen KJRose-John SMullberg J1999. Immunoadhesins of interleukin-6 and the IL-6/soluble IL-6R fusion protein hyper-IL-6J Immunol Methods2232171-183. Jostock T, Blinn G, Renne C, Kallen KJ, Rose-John S, Mullberg J. 1999. Immunoadhesins of interleukin-6 and the IL-6/soluble IL-6R fusion protein hyper-IL-6. J Immunol Methods 223(2):171–183.
Jostock TMüllberg JÖzbek SAtreya RBlinn GVoltz NFischer MMarkus FRose-John S2001a. Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responsesEur J Biochem2681160-167. Jostock T, Müllberg J, Özbek S, Atreya R, Blinn G, Voltz N, Fischer M, Markus F, Rose-John S. 2001a. Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses. Eur J Biochem 268(1):160–167.
Jostock TMüllberg JÖzbek SAtreya RBlinn GVoltz NFischer MNeurath MFRose-John S2001b. Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responsesEur J Biochem2681160-167. Jostock T, Müllberg J, Özbek S, Atreya R, Blinn G, Voltz N, Fischer M, Neurath MF, Rose-John S. 2001b. Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses. Eur J Biochem 268(1):160–167.
Kishimoto TAkira SNarazaki MTaga T1995. Interleukin-6 family of cytokines and gp130Blood8641243-1254. Kishimoto T, Akira S, Narazaki M, Taga T. 1995. Interleukin-6 family of cytokines and gp130. Blood 86(4):1243–1254.
Kristiansen OPMandrup-Poulsen T2005. Interleukin-6 and diabetes: the good, the bad, or the indifferent?Diabetes 54 Suppl2S114-S124. Kristiansen OP, Mandrup-Poulsen T. 2005. Interleukin-6 and diabetes: the good, the bad, or the indifferent? Diabetes 54 Suppl 2:S114–S124.
Laaksovirta HSoinila SHukkanen VRöyttä MSoilu-Hänninen M2008. Serum level of CNTF is elevated in patients with amyotrophic lateral sclerosis and correlates with site of disease onsetEur J Neurol154355-359. Laaksovirta H, Soinila S, Hukkanen V, Röyttä M, Soilu-Hänninen M. 2008. Serum level of CNTF is elevated in patients with amyotrophic lateral sclerosis and correlates with site of disease onset. Eur J Neurol 15(4):355-359.
Lee HKSeo IAShin YKPark JWSuh DJPark HT2009. Capsaicin inhibits the IL-6/STAT3 pathway by depleting intracellular gp130 pools through endoplasmic reticulum stressBiochem Biophys Res Commun3822445-450. Lee HK, Seo IA, Shin YK, Park JW, Suh DJ, Park HT. 2009. Capsaicin inhibits the IL-6/STAT3 pathway by depleting intracellular gp130 pools through endoplasmic reticulum stress. Biochem Biophys Res Commun 382(2):445–450.
Lee SOLou WQureshi KMMehraein-Ghomi FTrump DLGao AC2004. RNA interference targeting Stat3 inhibits growth and induces apoptosis of human prostate cancer cellsProstate604303-309. Lee SO, Lou W, Qureshi KM, Mehraein-Ghomi F, Trump DL, Gao AC. 2004. RNA interference targeting Stat3 inhibits growth and induces apoptosis of human prostate cancer cells. Prostate 60(4):303–309.
Lin MRose-John SGrotzinger JConrad UScheller J2006. Functional expression of a biologically active fragment of soluble gp130 as an ELP-fusion protein in transgenic plants: purification via inverse transition cyclingBiochem J3983577-583. Lin M, Rose-John S, Grotzinger J, Conrad U, Scheller J. 2006. Functional expression of a biologically active fragment of soluble gp130 as an ELP-fusion protein in transgenic plants: purification via inverse transition cycling. Biochem J 398(3):577–583.
Genovese MCMcKay JDNasonov ELMysler EFda Silva NAAlecock EWoodworth TGomez-Reino JJ2008. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy studyArthritis Rheum58102968-2980. Genovese MC, McKay JD, Nasonov EL, Mysler EF, da Silva NA, Alecock E, Woodworth T, Gomez-Reino JJ. 2008. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum 58(10):2968–2980.
Mochizuki YOkamura YIida HMori HShimada K1998. Interleukin-6 and “complex” cardiac myxomaAnn Thorac Surg663931-933. Mochizuki Y, Okamura Y, Iida H, Mori H, Shimada K. 1998. Interleukin-6 and “complex” cardiac myxoma. Ann Thorac Surg 66(3):931–933.
Muller-Newen GKuster AHemmann UKeul RHorsten UMartens AGraeve LWijdenes JHeinrich PC1998. Soluble IL-6 receptor potentiates the antagonistic activity of soluble gp130 on IL-6 responsesJ Immunol161116347-6355. Muller-Newen G, Kuster A, Hemmann U, Keul R, Horsten U, Martens A, Graeve L, Wijdenes J, Heinrich PC. 1998. Soluble IL-6 receptor potentiates the antagonistic activity of soluble gp130 on IL-6 responses. J Immunol 161(11):6347–6355.
Narazaki MYasukawa KSaito TOhsugi YFukui HKoishihara YYancopoulos GDTaga TKishimoto T1993. Soluble forms of the interleukin-6 signal-transducing receptor component gp130 in human serum possessing a potential to inhibit signals through membrane-anchored gp130Blood8241120-1126. Narazaki M, Yasukawa K, Saito T, Ohsugi Y, Fukui H, Koishihara Y, Yancopoulos GD, Taga T, Kishimoto T. 1993. Soluble forms of the interleukin-6 signal-transducing receptor component gp130 in human serum possessing a potential to inhibit signals through membrane-anchored gp130. Blood 82(4):1120–1126.
Nishimoto NKishimoto T2008Therapeutic antibodiesBerlin, HeidelbergSpringer. Nishimoto N, Kishimoto T. 2008. Therapeutic antibodies. Berlin, Heidelberg: Springer.
Nishimoto NKishimoto TYoshizaki K2000. Anti-interleukin 6 receptor antibody treatment in rheumatic diseaseAnn Rheum Dis59suppli21-i27. Nishimoto N, Kishimoto T, Yoshizaki K. 2000. Anti-interleukin 6 receptor antibody treatment in rheumatic disease. Ann Rheum Dis 59(suppl):i21–i27.
Nishimoto NYoshizaki KMiyasaka NYamamoto KKawai STakeuchi THashimoto JAzuma JKishimoto T2004. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trialArthritis Rheum5061761-1769. Nishimoto N, Yoshizaki K, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Hashimoto J, Azuma J, Kishimoto T. 2004. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 50(6):1761–1769.
Ohtani TIshihara KAkira SYamanaka Y et al.2000. gp130-mediated signalling as a therapeutic targetExpert Opin Threr Targets44459-479. Ohtani T, Ishihara K, Akira S, Yamanaka Y, et al. 2000. gp130-mediated signalling as a therapeutic target. Expert Opin Threr Targets 4(4):459–479.
Pflanz SKurth IGrotzinger JHeinrich PCMuller-Newen G2000. Two different epitopes of the signal transducer gp130 sequentially cooperate on IL-6-induced receptor activationJ Immunol165127042-7049. Pflanz S, Kurth I, Grotzinger J, Heinrich PC, Muller-Newen G. 2000. Two different epitopes of the signal transducer gp130 sequentially cooperate on IL-6-induced receptor activation. J Immunol 165(12):7042–7049.
Rabe BChalaris AMay UWaetzig GHSeegert DWilliams ASJones SARose-John SScheller J2008. Transgenic blockade of interleukin 6 transsignaling abrogates inflammationBlood11131021-1028. Rabe B, Chalaris A, May U, Waetzig GH, Seegert D, Williams AS, Jones SA, Rose-John S, Scheller J. 2008. Transgenic blockade of interleukin 6 transsignaling abrogates inflammation. Blood 111(3):1021–1028.
Rebouissou CWijdenes JAutissier PTarte KCostes VLiautard JRossi JFBrochier JKlein B1998. A gp130 interleukin-6 transducer-dependent SCID model of human multiple myelomaBlood91124727-4737. Rebouissou C, Wijdenes J, Autissier P, Tarte K, Costes V, Liautard J, Rossi JF, Brochier J, Klein B. 1998. A gp130 interleukin-6 transducer-dependent SCID model of human multiple myeloma. Blood 91(12):4727–4737.
Savino RCiapponi LLahm ADemartis ACabibbo AToniatti CDelmastro PAltamura SCiliberto G1994. Rational design of a receptor super-antagonist of human interleukin-6EMBO J13245863-5870. Savino R, Ciapponi L, Lahm A, Demartis A, Cabibbo A, Toniatti C, Delmastro P, Altamura S, Ciliberto G. 1994. Rational design of a receptor super-antagonist of human interleukin-6. EMBO J 13(24):5863–5870.
Selander KSLi LWatson LMerrell MDahmen HHeinrich PCMuller-Newen GHarris KW2004. Inhibition of gp130 signaling in breast cancer blocks constitutive activation of Stat3 and inhibits in vivo malignancyCancer Res64196924-6933. Selander KS, Li L, Watson L, Merrell M, Dahmen H, Heinrich PC, Muller-Newen G, Harris KW. 2004. Inhibition of gp130 signaling in breast cancer blocks constitutive activation of Stat3 and inhibits in vivo malignancy. Cancer Res 64(19):6924–6933.
Smith PCHobisch ALin DLCulig ZKeller ET2001. Interleukin-6 and prostate cancer progressionCytokine Growth Factor Rev12133-40. Smith PC, Hobisch A, Lin DL, Culig Z, Keller ET. 2001. Interleukin-6 and prostate cancer progression. Cytokine Growth Factor Rev 12(1):33–40.
Sobota RSzwed MKasza ABugno MKordula T2000. Parthenolide inhibits activation of signal transducers and activators of transcription (STATs) induced by cytokines of the IL-6 familyBiochem Biophys Res Commun2671329-333. Sobota R, Szwed M, Kasza A, Bugno M, Kordula T. 2000. Parthenolide inhibits activation of signal transducers and activators of transcription (STATs) induced by cytokines of the IL-6 family. Biochem Biophys Res Commun 267(1):329–333.
Tackey ELipsky PEIllei GG2004. Rationale for interleukin-6 blockade in systemic lupus erythematosusLupus135339-343. Tackey E, Lipsky PE, Illei GG. 2004. Rationale for interleukin-6 blockade in systemic lupus erythematosus. Lupus 13(5):339–343.
Taga THibi MHirata YYamasaki KYasukawa KMatsuda THirano TKishimoto T1989. Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130Cell58573-581. Taga T, Hibi M, Hirata Y, Yamasaki K, Yasukawa K, Matsuda T, Hirano T, Kishimoto T. 1989. Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130. Cell 58:573–581.
Tanaka MKishimura MOzaki SOsakada FHashimoto HOkubo MMurakami MNakao K2000. Cloning of novel soluble gp130 and detection of its neutralizing autoantibodies in rheumatoid arthritisJ Clin Invest1061137-144. Tanaka M, Kishimura M, Ozaki S, Osakada F, Hashimoto H, Okubo M, Murakami M, Nakao K. 2000. Cloning of novel soluble gp130 and detection of its neutralizing autoantibodies in rheumatoid arthritis. J Clin Invest 106(1):137–144.
Tenhumberg SWaetzig GHChalaris ARabe BSeegert DScheller JRose-John SGrotzinger J2008. Structure-guided optimization of the interleukin-6 trans-signaling antagonist sgp130J Biol Chem2834027200-27207. Tenhumberg S, Waetzig GH, Chalaris A, Rabe B, Seegert D, Scheller J, Rose-John S, Grotzinger J. 2008. Structure-guided optimization of the interleukin-6 trans-signaling antagonist sgp130. J Biol Chem 283(40):27200–27207.
Varga VLFülöp AKHolub MCTóth SSzalai CFalus A2001. Gp130-specific antisense oligonucleotides inhibit IL-6 signal inducing JUNB mRNAtranscription in the human heptatoma cell line, HEPG2Cell Biol Int258835-840. Varga VL, Fülöp AK, Holub MC, Tóth S, Szalai C, Falus A. 2001. Gp130-specific antisense oligonucleotides inhibit IL-6 signal inducing JUNB mRNAtranscription in the human heptatoma cell line, HEPG2. Cell Biol Int 25(8):835–840.
Vernallis ABHudson KRHeath JK1997. An antagonist for the leukemia inhibitory factor receptor inhibits leukemia inhibitory factor, cardiotrophin-1, ciliary neurotrophic factor, and oncostatin MJ Biol Chem2724326947-26952. Vernallis AB, Hudson KR, Heath JK. 1997. An antagonist for the leukemia inhibitory factor receptor inhibits leukemia inhibitory factor, cardiotrophin-1, ciliary neurotrophic factor, and oncostatin M. J Biol Chem 272(43):26947–26952.
Weerasinghe PLi YGuan YZhang RTweardy DJJing N2008. T40214/PEI complex: a potent therapeutics for prostate cancer that targets STAT3 signalingProstate68131430-1442. Weerasinghe P, Li Y, Guan Y, Zhang R, Tweardy DJ, Jing N. 2008. T40214/PEI complex: a potent therapeutics for prostate cancer that targets STAT3 signaling. Prostate 68(13):1430–1442.
Yokota S2008. [Interleukin-6 as a pathogenic factor of systemic-onset juvenile idiopathic arthritis]Nihon Rinsho Meneki Gakkai Kaishi31299-103. Yokota S. 2008. [Interleukin-6 as a pathogenic factor of systemic-onset juvenile idiopathic arthritis]. Nihon Rinsho Meneki Gakkai Kaishi 31(2):99–103.
Yu HPardoll DJove R2009. STATs in cancer inflammation and immunity: a leading role for STAT3Nat Rev Cancer911798-809. Yu H, Pardoll D, Jove R. 2009. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 9(11):798–809.
Information & Authors
Information
Published In
Journal of Interferon & Cytokine Research
Volume 30 • Issue Number 12 • December 2010
Pages: 865 - 873
PubMed: 20979530
Copyright
Copyright 2010, Mary Ann Liebert, Inc.
History
Published in print: December 2010
Published online: 1 December 2010
Published ahead of print: 27 October 2010
Accepted: 21 May 2010
Received: 19 March 2010
Authors
Author Disclosure Statement
No competing financial interests exist.
Metrics & Citations
Metrics
Citations
Export Citation
Export citation
Select the format you want to export the citations of this publication.
View Options
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.⚠ Society Access
If you are a member of a society that has access to this content please log in via your society website and then return to this publication.